GeneFab is a contract manufacturing and synthetic biology biofoundry specializing in cell and gene therapies. Established in 2023, GeneFab merges expertise in synthetic biology with advanced cGMP capabilities to expedite the development and commercialization of genetic medicines. The company offers a comprehensive technology platform that encompasses early-stage product design, technical development, and cGMP-compliant production. Its innovative platform features bioinformatics-guided discovery of cell type promoters, directed evolution of small molecule-regulated gene switches, and the engineering of sensitive kill switches for improved safety and control in cellular therapies. GeneFab values diversity and inclusion, recognizing that varied perspectives lead to better ideas and a more dynamic workplace. They are committed to creating an environment where all individuals feel welcome and empowered to contribute.